Table 2

The functional microRNA aberrations in cutaneous T-cell lymphomas

MicroRNA	Expression	Function*	Confirmed target*	Potential clinical value	Disease	References
MiR-155	Over-	OG	SATB1	Phase 1 trial of cobomarsen	MFt, SS, PCALCL	^97–101
MiR-106b	Over-	OG	PTEN		SS	¹⁷⁴
MiR-199a-3p	Over-	Unidentified	EVL		SS	^105,175
MiR-181a/b	Over-	Unidentified	SAMHD1		MFt, SS	^97,175,176
MiR-125b-5p		OG	MAD4	Chemotherapy resistance	CTCL	¹¹⁰
MiR-122	Over-	OG		Chemotherapy resistance	MFt	¹⁰⁹
MiR-21	Over-	OG		Prognosis	MFt, SS, PCALCL	^97,104,105
MiR-486	Over-	OG			SS	¹⁰⁴
MiR-142-3p/5p	Over-	OG			MFt, PCALCL	^97,104
MiR-214	Over-	OG			SS	^104,106
MiR-150	Down-	TS	CCR6		Stage IV MF, SS	^114,175
MiR-29b	Down-	TS	BRD4		MF, SS, PCALCL	^15,111
MiR-16	Down-	TS	BMI1		MF, SS	^117,175
MiR-223	Down-	TS	TOX		MF, SS	^112,175
MiR-200c	Down-	TS	JAG1		MF, SS, PCALCL	^97,116
Let-7a, let-7d and let-7f	Down-	Unidentified		Let-7a for prognosis	MFt	¹²⁷

OG, oncogene; MFt, tumor-stage mycosis fungoides; SS, Sézary syndrome; PCALCL, primary cutaneous anaplastic large cell lymphoma; CTCL, cutaneous T-cell lymphoma; MF, mycosis fungoides; TS, tumor suppressor. *All of the confirmed targets and functions of microRNAs have been validated by experimental data of CTCLs.